Related Experiment Video
Updated: Aug 18, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Treatment of cardiogenic shock with the Hemopump left ventricular assist device
R K Wampler1, O H Frazier, A M Lansing
1Nimbus, Inc, Rancho Cordova, California.
Insights
The Hemopump device significantly improves hemodynamic status in patients with cardiogenic shock. This study suggests the Hemopump may enhance survival rates for select patients with severe heart conditions.
Area of Science:
- Cardiology
- Medical Devices
- Mechanical Circulatory Support
Background:
- Cardiogenic shock is a life-threatening condition with high mortality.
- Conventional therapies for cardiogenic shock have limited efficacy.
- The Hemopump is a percutaneous ventricular assist device designed for hemodynamic support.
Purpose of the Study:
- To evaluate the safety and efficacy of the Hemopump in patients with refractory cardiogenic shock.
- To assess the impact of Hemopump assistance on hemodynamic parameters.
- To determine the 30-day survival rate in patients treated with the Hemopump.
Main Methods:
- A multi-institutional study involving 53 patients with refractory cardiogenic shock.
- Hemodynamic criteria for cardiogenic shock included low cardiac index, high pulmonary capillary wedge pressure, and low systolic blood pressure or left ventricular work index.
- Successful Hemopump insertion in 77.3% of patients, with hemodynamic monitoring and survival assessment.
Main Results:
- Significant improvement in hemodynamic status was observed during Hemopump assistance.
- Minimal hemolysis and no leg ischemia were reported.
- The 30-day overall survival rate for the Hemopump group was 31.7%.
Conclusions:
- The Hemopump provides significant hemodynamic support in cardiogenic shock.
- It facilitates recovery in marginal ventricles and may improve survival in select patients.
- Proposed criteria for Hemopump indications and clinical utility warrant further investigation.
Abstract:
A multiinstitutional study is in progress to evaluate the Hemopump in the treatment of cardiogenic shock. Fifty-three patients with refractory cardiogenic shock were selected for Hemopump assistance. The hemodynamic definition of cardiogenic shock included (1) a cardiac index of less than 2.0 L.min-1.m-2, (2) pulmonary capillary wedge pressure of greater than 18 mm Hg, and (3) a systolic blood pressure of less than 90 mm Hg or a left ventricular work index of less than 1,500 g-m.m-2.min-1. The Hemopump was successfully inserted in 41 of 53 patients (77.3%). A significant improvement in the hemodynamic status was seen during Hemopump assistance. A minimal level of hemolysis was observed. No leg ischemia was observed. The 30-day overall survival of the Hemopump group was 31.7%. Criteria establishing indications for use and clinical utility are proposed. We conclude that the Hemopump provides significant hemodynamic support of the patient in cardiogenic shock allowing for recovery from ventricular stunning in marginal ventricles, and that in select patients the Hemopump may offer a major improvement in survival over conventional therapy.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

